伊曲康唑治疗重症肝病并发肺部真菌感染患者的临床疗效分析

Clinical effect of itraconazole in the treatment of severe liver disease complicated with pulmonary fungal infection

目的:探讨伊曲康唑治疗重症肝病并发肺部真菌感染患者的临床效果。方法:选取2016年1月至2019年2月在我院治疗的重症肝病并发肺部真菌感染患者89例,根据治疗方案分为试验组(n=44)和对照组(n=45),试验组患者给予伊曲康唑治疗,对照组患者给予氟康唑治疗,疗程28 d,检测治疗前后患者细胞免疫功能及胸部影像学变化,对比两组患者治疗疗效、不良反应。结果:试验组患者疗效优于对照组(P<0.05),其总有效率为84.09%;试验组患者治疗后CD_(3)^(+)和CD_(4)^(+)分别为(65.50±6.68)%和(39.30±7.22)%,明显高于对照组(P<0.05),而CD 8+为(25.50±3.39)%,明显低于对照组(P<0.05);试验组患者治疗后胸部影像渗出、空洞比例分别为31.82%和29.55%,明显少于对照组(P<0.05);试验组和对照组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:伊曲康唑治疗重症肝病并发肺部真菌感染患者有较好的临床效果,值得临床推广。

Objective:To explore the clinical effect of itraconazole in the treatment of severe liver disease complicated with pulmonary fungal infection.Methods:From January 2016 to February 2019,89 patients with severe liver disease complicated with pulmonary fungal infection were selected,according to the treatment plan,the patients were divided into experimental group(n=44)and the control group(n=45),the experimental group was treated with itraconazole and the control group with fluconazole,the therapeutic effect,side effects and chest image of the two groups were observed,the cellular immune function was detected before and after treatment.Results:The therapeutic effect of the experimental group was better than that of the control group(P<0.05),the total effective rate was 84.09%;CD_(3)^(+) and CD_(4)^(+) in the Experimental group after treatment were(65.50±6.68)% and(39.30±7.22)%,which were significantly higher than those in the control group(P<0.05),while CD 8+was(25.50±3.39)%,which was significantly lower than those in the control group(P<0.05);The rate of exudation and cavity in the Experimental group after treatment were 31.82% and 29.55%,which were significantly lower than that in the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the Experimental group and the control group(P>0.05).Conclusion:Itraconazole has a good clinical effect in the treatment of severe liver disease complicated with a pulmonary fungal infection,which is worthy of clinical use.